0001104659-23-088394.txt : 20230807 0001104659-23-088394.hdr.sgml : 20230807 20230807165009 ACCESSION NUMBER: 0001104659-23-088394 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230804 ITEM INFORMATION: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20230807 DATE AS OF CHANGE: 20230807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apollo Medical Holdings, Inc. CENTRAL INDEX KEY: 0001083446 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 870042699 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37392 FILM NUMBER: 231148235 BUSINESS ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 BUSINESS PHONE: (626) 282-0288 MAIL ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 FORMER COMPANY: FORMER CONFORMED NAME: SICLONE INDUSTRIES INC DATE OF NAME CHANGE: 19990413 8-K 1 tm2323017d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 4, 2023

APOLLO MEDICAL HOLDINGS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-37392	95-4472349
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of Principal Executive Offices) (Zip Code)

(626) 282-0288

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	AMEH	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 4.02

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

Restatement of Historical Financial Results

On August 4, 2023, the Audit Committee of the Board of Directors (the “Audit Committee”) of Apollo Medical Holdings, Inc. (the “Company”), based on the recommendation of, and after consultation with, the Company’s management, concluded that the Company’s previously issued audited consolidated financial statements as of December 31, 2022 and 2021 and for each of the years ended December 31, 2022, 2021 and 2020, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”), and the Company’s unaudited consolidated financial statements included in the Quarterly Reports on Form 10-Q for the quarterly 2022 fiscal year periods (the “Historical Quarterly Reports”), as well as the unaudited consolidated financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Q1 Quarterly Report” and, together with the 2022 Annual Report and the Historical Quarterly Reports, the “Reports” and all financial statements included in the Reports, collectively, the “Affected Financials”), should no longer be relied upon due to material unintentional errors related to the Company’s tax provision. Similarly, related earnings releases, press releases, shareholder communications, investor presentations or other communications describing relevant portions of the Affected Financials should no longer be relied upon.

In the second quarter of 2023, the Company began a review of its income tax filing structure, and related accounting matters, with the assistance of outside consultants. In connection with such review, the Company identified unintentional errors in its accounting for the income tax effects of certain intercompany dividends and certain net operating losses. Specifically, the Company failed to accrue for income tax expense on certain intercompany dividends. Although the Company accrued taxes on the income generated by the subsidiary that made the intercompany dividend, the additional taxes due by the subsidiary entitled to the dividend were not accrued. Also, based on a review of historical tax filings, the Company concluded that its previous determination regarding the realizability of certain net operating losses was incorrect resulting in an overstatement of the valuation allowance with respect to such net operating losses. The errors resulted in a net understatement of income tax expense in prior periods and also had an impact on purchase accounting (goodwill) as a portion of the net operating losses affected by the errors pertained to acquisitions in prior periods. The Company has determined that the adjustments as of December 31, 2022 and 2021 and for the years ended December 31, 2022, 2021, and 2020, and the first quarter of 2023 were material and will require restatement.

The Company expects to record decreases to previously reported net income of $0.2 million in 2020, $3.2 million in 2021, $4.8 million in 2022, and $1.8 million in the first quarter of 2023. Certain GAAP and non-GAAP measures previously presented by the Company, including revenue, gross profit, pretax income from continuing operations, EBITDA and Adjusted EBITDA, are not expected to be impacted by the restatement. The Company is evaluating changes to its tax structure to reduce the current effective tax rate and amount of cash taxes.

Controls and Procedures

In connection with the restatement, management has re-evaluated the effectiveness of the Company’s disclosure controls and procedures. Management has concluded that the Company’s disclosure controls and procedures were not effective as of December 31, 2022, due to a material weakness in its internal control over financial reporting related to the ineffective design of controls related to income taxes. As a result of this newly identified material weakness, Management’s Annual Report on Internal Control Over Financial Reporting and Ernst & Young LLP’s, the Company’s independent registered public accounting firm, opinion on the effectiveness of the Company’s internal control over financial reporting as of December 31, 2022, included in the 2022 Annual Report, should no longer be relied upon. The Company will provide further specifics on the material weakness in its internal control over financial reporting and its disclosure controls and procedures, and its plan for remediation, in its amendment to the 2022 Annual Report.

The Company’s management and Audit Committee discussed the matters disclosed in this Item 4.02 with Ernst & Young LLP.

Next Steps

As a result of the misstatements, the Company plans to restate its consolidated financial statements as of December 31, 2022 and 2021 and for each of the years ended December 31, 2022, 2021 and 2020, as well as Management’s Annual Report on Internal Control Over Financial Reporting as of December 31, 2022, and include them in an amendment to the 2022 Annual Report to be filed with the Securities and Exchange Commission as soon as practicable. Additionally, the Company plans to restate its unaudited consolidated financial statements for the quarter ended March 31, 2023 and include them in an amendment to the Q1 Quarterly Report to be filed with the Securities and Exchange Commission as soon as practicable. The Company expects to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, which will include recast financial statements for the second quarter of 2022, reflecting the restated financial information.

Item 7.01

Regulation FD Disclosure.

The error and the accounting treatment contemplated by the restatement described in Item 4.02 above have no impact on the Company’s previously communicated fiscal 2023 outlook.

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the Company’s expectations and preliminary estimates of the impact of the restatement on the Affected Financials; the scope of the restatement and the controls and procedures deficiencies; the timing of the completion of the restatement and the filing of restated financial statements; plans to remediate the deficiencies, including the material weakness, with respect to the Company’s internal control over financial reporting and disclosure controls and procedures, including potential changes to its tax structure; the impact of these matters on the Company’s performance and outlook; and any statements or assumptions underlying any of the foregoing. The estimates included in this report are preliminary and are subject to change as the Company completes its financial close process. You can identify forward looking statements by the fact that they do not relate strictly to historical or current facts. Forward-looking statements may be identified by the use of forward-looking terms, such as “anticipate,” “could,” “can,” “may,” “might,” “potential,” “predict,” “should,” “estimate,” “expect,” “project,” “believe,” “think,” “plan,” “envision,” “intend,” “continue,” “target,” “seek,” “contemplate,” “budgeted,” “will,” or “would,” and the negative of such terms, other variations on such terms or other similar or comparable words, phrases, or terminology. The Company cannot assure you that future developments affecting it will be those that it has anticipated. Important risks and uncertainties that could cause actual results to differ materially from the Company’s expectations include, among others, risks related to the timely and correct completion of the restatement and related filings; identification of errors in the Company’s financial reporting in the future that require the Company to restate previously issued financial statements, which may subject the Company to unanticipated costs or regulatory penalties and could cause investors to lose confidence in the accuracy and completeness of the Company’s financial statements; the risk that additional information may become known prior to the expected filing with the Securities and Exchange Commission of the periodic reports described herein or that other subsequent events may occur that would require the Company to make additional adjustments to its financial statements or delay the filing of the corrected or future periodic reports with the Securities and Exchange Commission; risks related to changes in the effects of the restatement on the Affected Financials or financial results; the risk that the Company will be unable to obtain, if needed, any required waivers under its credit agreement; risks related to higher than expected charges after completing the restatement process; risks related to delays in the filing of the restated financial statements; risks related to the Company’s ability to implement and maintain effective internal control over financial reporting in the future, which may adversely affect the accuracy and timeliness of the Company’s financial reporting; risks related to changes in accounting rules or regulations; risks related to fluctuations in the Company’s tax obligations and effective tax rate and realization of the Company’s deferred tax assets, including net operating loss carryforwards, which may result in volatility of the Company’s results of operations; risks relating to the Company’s complex legal structure, which may cause tax authorities to question or disagree with the Company’s tax status, potentially adversely impacting the Company; risks related to the Company’s plans to remediate any control and procedures deficiencies; risks related to the timing and results of the Company’s review of the effectiveness of internal control over financial reporting and related disclosure controls and procedures; risks related to whether a restatement of financial results will be required for other accounting issues; risks related to the application of accounting or tax principles in an unanticipated manner; risks related to the Company’s dependence on key personnel and any changes in the Company’s ability to retain key personnel; as well as those risks and uncertainties discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 1, 2023, including the risk factors discussed under the heading “Risk Factors” in Part I, Item IA thereof, and similar disclosures in subsequent reports filed with the Securities and Exchange Commission. Any forward-looking statement made by the Company in this report speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	APOLLO MEDICAL HOLDINGS, INC.

Date: August 7, 2023	By:	/s/ Thomas S. Lam
	Name:	Thomas S. Lam, M.D., M.P.H.
	Title:	Co-Chief Executive Officer and President

EX-101.SCH 2 ameh-20230804.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 ameh-20230804_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 ameh-20230804_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Aug. 04, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 04, 2023
Entity File Number	001-37392
Entity Registrant Name	APOLLO MEDICAL HOLDINGS, INC.
Entity Central Index Key	0001083446
Entity Tax Identification Number	95-4472349
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1668 S. Garfield Avenue
Entity Address, Address Line Two	2nd Floor
Entity Address, City or Town	Alhambra
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91801
City Area Code	626
Local Phone Number	282-0288
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	AMEH
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 6 tm2323017d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001083446 2023-08-04 2023-08-04 iso4217:USD shares iso4217:USD shares 0001083446 false 8-K 2023-08-04 APOLLO MEDICAL HOLDINGS, INC. DE 001-37392 95-4472349 1668 S. Garfield Avenue 2nd Floor Alhambra CA 91801 626 282-0288 false false false false Common Stock AMEH NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $2&!U<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !$A@=7FX'P7.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>R$GV#Y/FLM+3!H,5-G8SMMJ:Q;&Q-9*^_1RO31G; ^QHZ>=/ MGT"M\D*Y@,_!>0QD,%Y-MA^B4'[%#D1> $1U0"MCF1)#:NY*4)45L&Z> MZ(]3W\(%,,,(@XW?!=0+,5?_Q.8.L%-RBF9)C>-8CDW.I1TJ>'MZ?,GK%F:( M) >%Z55^P\^;5Y6&\WK*MYW13\ON!WVYJ+&R[X]?OL^L/O(FR=-COS MCXW/@ET+O^ZB^P)02P,$% @ 1(8'5YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !$A@=7>U=H?%H$ /$0 & 'AL+W=O&$+V G.6\>'Y^\=C+82?6:;3G7Y#V.DFQH;;5.;VP[\[<\9MFE3'D" M9T*I8J:AJS9VEBK.@B(HCFSJ.%T[9B*Q1H/BV$*-!C+7D4CX0I$LCV.F/FYY M)'=#R[4^#[R(S5:; _9HD+(-7W+]1[I0T+-+E4#$/,F$3(CBX=#RW)M;>F4" MBBO^%'R7';6)&140*.'P=1J[RG"3QN M?ZK?%8.'P:Q9QL@B@!??^1@7EA&DV&BBY(\I<#6JF40RU MB 8XD9A966H%9P7$Z=%8OG$UL#5(F0.V?PB[W8?1$V%>OKDD3N>"4(>V_QMN M T&)04L,6NBU,0SRM[?.M(*)^J>.:*_0J5ZUO"$2GA.B@*AX0! 7%7<0V=11X M?,BBC",<5R7'U7G)6' E9$"F24"@^&KS@BL5953445,A=4NV+JHX3;30'^1. M1)P\Y?&ZOKAQ#<=Q6^WK=I\B/-6%R;*5S'6SS/Y\_D M<3J9C;TY>7B>3V9/]\L+,GL:7R*ET$:Q^B=4_!VO%WLDL #81"I\5=GYZVD-ZA/IACDD<>[YT!Z00#.F%U\ M-L@R5W22T<+N=%6Q:O%_V'!=CJY8-%_?\8@H] MV->>1L$%NA3S.[=:+USAA1M3*XN*%_5T)K MGD!BXCA/#OZ;U5+A0DW[#[=:%5S<>+]C3)6; MT[/=[1,BS?>M=3P_EPTMYQ!O9L+X'PHI?[LF)?H\AO(Z%]02P,$% @ M1(8'5Y^@&_"Q @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@ M;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W M)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP M4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W M8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM M5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLY MS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B M'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P M:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X M3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3 MB.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3 M_ 102P,$% @ 1(8'5Y>*NQS $P( L !?3T\$MP> M:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5; M&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI" M/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V, MYU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8I MGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48 MY0]02P,$% @ 1(8'5R0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB M688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4: MY$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[? M#'!X=/X!4$L#!!0 ( $2&!U=ED'F2&0$ ,\# 3 6T-O;G1E;G1? M5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS M3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV M(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U M2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z M6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1 M.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( $2& M!U=[5VA\6@0 \1 8 " @0X( !X;"]W;W)K# >&PO7BKL< MP !," + " 7H/ !?JQ"(6,P$ "(" / " 6,0 !X;"]W;W)K M8F]O:RYX;6Q02P$"% ,4 " !$A@=7)!Z;HJT #X 0 &@ M @ '#$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M" !$A@=799!YDAD! #/ P $P @ &H$@ 6T-O;G1E;G1? @5'EP97-=+GAM;%!+!08 "0 ) #X" #R$P ! end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://apollomed.net/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2323017d1_8k.htm ameh-20230804.xsd ameh-20230804_lab.xml ameh-20230804_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2323017d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2323017d1_8k.htm" ] }, "labelLink": { "local": [ "ameh-20230804_lab.xml" ] }, "presentationLink": { "local": [ "ameh-20230804_pre.xml" ] }, "schema": { "local": [ "ameh-20230804.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "AMEH", "nsuri": "http://apollomed.net/20230804", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2323017d1_8k.htm", "contextRef": "AsOf2023-08-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://apollomed.net/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2323017d1_8k.htm", "contextRef": "AsOf2023-08-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001104659-23-088394-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-088394-xbrl.zip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end